Development and Validation of a Prognostic Score for Hepatocellular Carcinoma Patients in Immune Checkpoint Inhibitors Therapies: The Hepatocellular Carcinoma Modified Gustave Roussy Immune Score

Background: There is not yet an effective marker in predicting the efficacy of immune checkpoint inhibitors (ICIs) in treating hepatocellular carcinoma (HCC) patients. The Gustave Roussy Immune Score (GRIm-Score) based on three objective variables, namely, neutrophil-to-lymphocyte ratio (NLR), serum...

Descripción completa

Detalles Bibliográficos
Autores principales: Li, Yongjiang, Pan, Yangxun, Lin, Ximeng, Hou, Jingyu, Hu, Zili, Xu, Li, Zhou, Zhongguo, Zhang, Yaojun, Chen, Minshan, Hu, Dandan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Pharmacology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8883391/
https://www.ncbi.nlm.nih.gov/pubmed/35237150
http://dx.doi.org/10.3389/fphar.2021.819985

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8883391/
https://www.ncbi.nlm.nih.gov/pubmed/35237150
http://dx.doi.org/10.3389/fphar.2021.819985

Ejemplares similares